ChemPartner has announced the appointment of Lilly Xu, PhD as President of Shanghai ChemPartner. 

Dr Lilly is a seasoned manager with a strong portfolio of success. She joined ChemPartner in 2017 to lead the strategic drug discovery services as Senior Vice President and Head of DMPK and Exploratory Toxicology. Prior to joining ChemPartner, Dr Lilly held various positions in US biotech and pharmaceutical companies including Amgen and Sanofi US.

Additionally, she was the Head of the Center for Predictive ADMET at Sanofi US, and she holds a green belt in Lean 6 Sigma. 

Dr Lilly earned a PhD in molecular and cellular biology from Saint Louis University in St Louis, Missouri. During her time in academia, she pioneered the use of human and animal hepatocytes in drug metabolism and drug-drug interactions.

As a leading, global CRO and CDMO, ChemPartner provides integrated life science services for drug discovery and development with expertise in discovery chemistry, biology, pharmacology, DMPK, exploratory toxicology, biologics discovery and development, and biologics manufacturing.